Abstract: This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 ?m to about 90 ?m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

Abstract: This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90 ranging from 35 ?m to 90 ?m as measured by laser light diffraction and wherein the tablet has a gemcabene dissolution profile characterized by a % dissolution profile of at least 80% in pH 5.0 potassium acetate buffer at 37° C.±0.5° C. in no more than 45 minutes as measured by ultra-violet/visible light absorption using a detection wavelength range of 216 nm to 230 nm. This invention further provides gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6. The tablets and gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6 are useful for treating or preventing liver disease or an abnormal liver condition, a disorder of lipoprotein or glucose metabolism, a cardiovascular or related vascular disorder, a disease caused by fibrosis (such as liver fibrosis), or a disease associated with inflammation (such as liver inflammation).

Abstract: This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 ?m to about 90 ?m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

Abstract: The present invention provides pharmaceutical compositions comprising a statin and an outer coating, and optionally gemcabene, and methods of use thereof.

Abstract: The present invention provides pharmaceutical compositions formulated to include a statin and gemcabene, wherein the composition is useful for treating, preventing, or reducing the symptoms of cardiovascular and metabolic indications that involve elevate levels of LDL cholesterol, triglycerides, or both.

Abstract: This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 ?m to about 90 ?m, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Abstract: The invention is a pharmaceutical composition comprising an Lp(a) inhibitor and a statin which inhibits HMG-CoA reductase, said composition being useful for treating vascular diseases.

Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Abstract: The present invention provides a method for treating or preventing the onset of Alzheimer's Disease comprising administering to a mammal in need thereof an Alzheimer's Disease-preventing or treating amount of a plasma-triglyceride level-lowering agent. Optionally, the plasma-triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent.

Abstract: The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.

Abstract: The present invention provides a method for treating or preventing the onset of Alzheimer's Disease comprising administering to a mammal in need thereof an Alzheimer's Disease-preventing or treating amount of a plasma-triglyceride level-lowering agent. Optionally, the plasma-triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent.

Abstract: Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.

Abstract: A method for introducing a scavenger receptor gene into a mammal to make said mammal resistant to atherosclerosis; an artificial scavenger receptor minigene or partial minigene as well as the ectopic expression of a scavenger receptor in the liver of a mammal for the reduction of apo B containing lipoproteins, elevation of high-density lipoprotein cholesterol, and prevention of atherosclerosis; and a method of treating atherosclerosis, hyperbetalipoproteinemia (i.e., high-levels of apolipoprotein (apo) B containing lipoproteins), hypercholesterolemia, hypertriglyceridemia; hypoalphalipoproteinemia (i.e., low levels of high-density lipoprotein), vascular complications of diabetes, transplant, atherectomy, and angioplastic restenosis in a patient with a therapeutically effective amount of a scavenger receptor gene alone or combined with a ACAT inhibitor, a HMG-CoA reductase inhibitor, a bile acid sequestrant, or lipid regulator, and pharmaceutical delivery methods which include these agents.

Abstract: This invention relates to a method of treating vascular proliferative responses in a patient that comprises intravenously administering to the patient a proliferative response inhibiting amount of poly(arginine).

Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.

Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.

Abstract: Dialkyl ethers lower Lp(a) and triglycerides, and elevate HDL-cholesterol, and are thereby useful for treating vascular diseases and noninsulin-dependent diabetes mellitus.